Journal
CURRENT OPINION IN RHEUMATOLOGY
Volume 25, Issue 6, Pages 700-706Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.bor.0000434668.32150.e5
Keywords
gastrointestinal involvement; outcome measures; systemic sclerosis; UCLA SCTC GIT 2; 0
Categories
Funding
- NIH/NIAMS [K24 AR063120]
Ask authors/readers for more resources
Purpose of reviewGastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication. This review discusses the outcome measures to capture GIT involvement in clinical care and trials.Recent findingsPatient-reported outcome measures have been validated (UCLA Scleroderma Clinical Trial Consortium GIT 2.0 and NIH PROMIS scales) in SSc-GIT. Multiple objective measures are available to assess mucosal involvement and motility in GIT. However, these need to be validated in SSc for trials.SummaryGIT is a common cause of morbidity and has negative impact on quality of life in SSc. Recommendations are given for trial design and evaluation of GIT involvement in SSc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available